Ascendis Pharma is a biopharmaceutical company developing novel therapies utilizing its proprietary TransCon technology platform. The company focuses on advancing product candidates in Endocrinology Rare Disease and Oncology through clinical development. This technology aims to improve treatment safety, efficacy, tolerability, and convenience for patients with unmet medical needs.

BioAtla develops Conditionally Active Biologics (CABs) that are engineered to activate selectively in the tumor microenvironment, enhancing tumor selectivity and reducing on-target toxicity. This technology aims to improve the therapeutic index of cancer treatments, providing safer and more effective immunotherapies.

CG Oncology develops Cretostimogene, an intravesically delivered oncolytic immunotherapy for non‑muscle invasive bladder cancer (NMIBC). The therapy uses a genetically engineered virus to directly lyse tumor cells and stimulate a systemic immune response, aiming to reduce recurrence and preserve the bladder. It is being evaluated in a comprehensive clinical program for safety and efficacy, targeting urologists, oncologists, and healthcare systems seeking bladder‑sparing treatments.

Neuron23 develops precision medicines targeting genetically defined neurological diseases, specifically Parkinson's and Alzheimer's, by utilizing advanced data science and human genetics to identify novel molecular targets. Their approach aims to create effective treatments that address the unmet medical needs of patients suffering from these debilitating conditions.

ONK Therapeutics develops off‑the‑shelf, genetically engineered natural killer (NK) cell therapies that are optimized for enhanced tumor homing, persistence, and resistance to exhaustion. Their proprietary platform creates dual‑targeted NK cells with modifications such as CISH knockout, enabling simultaneous recognition of multiple cancer antigens and scalable, rapid deployment for solid and hematologic tumors. The therapies are designed for integration with other modalities, including bispecific antibodies, to improve anti‑cancer efficacy.

OnKure Therapeutics discovers and develops tumor‑agnostic small‑molecule therapies that target shared oncogenic driver mutations across cancer types. It leverages pan‑cancer genomic mining, structure‑based drug design, and preclinical models (PDX, organoids) to validate compounds and co‑develop companion diagnostics, enabling biomarker‑driven adaptive trials for oncology clinicians and pharmaceutical partners.

Q32 Bio develops targeted biotherapeutics that re-regulate immune function to treat severe autoimmune and inflammatory diseases. Their lead candidates, Bempikibart and ADX-097, are designed to modulate adaptive and innate immune responses, respectively, addressing conditions such as atopic dermatitis and ANCA-Associated Vasculitis.

Y-mAbs is a clinical-stage biopharmaceutical company developing antibody immunotherapies targeting rare pediatric cancers, including neuroblastoma and osteosarcoma. Their treatments aim to improve survival rates and safety for patients facing these challenging conditions through ongoing clinical trials.